Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients (ZEAL)

December 23, 2024 updated by: Genzyme, a Sanofi Company

A Phase III, Randomized, Double-blinded, Parallel Group, Multi-centre Study to Assess the Efficacy and Safety of ZD6474 (ZACTIMA™) in Combination With Pemetrexed (Alimta®) Versus Pemetrexed Alone in Patients With Locally-Advanced or Metastatic NSCLC

Non-small cell lung cancer (NSCLC) can be treated with drugs that kill tumour cells, stop them from dividing, or stop the growth of the blood supply that cancers need to grow and spread. Clinical research has shown that drugs that inhibit vascular endothelial growth factor receptor (VEGFR) or epidermal growth factor receptor (EGFR) signalling can increase overall survival in patients with advanced non-small cell lung cancer (NSCLC). Preclinical studies have shown that vandetanib (ZD6474) is an inhibitor of both VEGFR and EGFR signalling. Giving vandetanib may therefore inhibit the growth of cancer cells by blocking their blood supply and by stopping them from dividing. This lung cancer study is to investigate if adding vandetanib to Alimta (pemetrexed) is more effective than Alimta (pemetrexed) alone.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

This randomized phase III non-small cell lung cancer clinical trial is studying the effect of Alimta (pemetrexed) plus vandetanib to see how well the combination works compared to Alimta (pemetrexed) alone in patients who have previously been treated for non-small cell lung cancer (NSCLC).

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
698

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Argentina
      • Avellaneda, Argentina
        • Research Site
      • Buenos Aires, Argentina
        • Research Site
      • Ciudad de Buenos Aires, Argentina
        • Research Site
      • Córdoba, Argentina
        • Research Site
      • La Plata, Argentina
        • Research Site
      • Ramos Mejía, Argentina
        • Research Site
      • Salta, Argentina
        • Research Site
      • Santa Fe, Argentina
        • Research Site
  • Australia
      • Chermside, Australia
        • Research Site
      • Fitzroy, Australia
        • Research Site
      • Footscray, Australia
        • Research Site
      • Heidelberg, Australia
        • Research Site
      • Randwick, Australia
        • Research Site
      • St. Leonards, Australia
        • Research Site
      • Wodonga, Australia
        • Research Site
  • Belgium
      • Brussels (Woluwé-St-Lambert), Belgium
        • Research Site
      • Leuven, Belgium
        • Research Site
      • Liège, Belgium
        • Research Site
  • Colombia
      • Bogota, Colombia
        • Research Site
      • Medellín, Colombia
        • Research Site
      • Pereira, Colombia
        • Research Site
      • Valledupar, Colombia
        • Research Site
  • France
      • Avignon Cedex 09, France
        • Research Site
      • Lyon Cedex 04, France
        • Research Site
      • Paris Cedex 15, France
        • Research Site
      • Pontoise Cedex, France
        • Research Site
      • Strasbourg Cedex, France
        • Research Site
  • Germany
      • Hannover, Germany
        • Research Site
      • Karlsruhe, Germany
        • Research Site
      • Kassel, Germany
        • Research Site
      • Köln, Germany
        • Research Site
      • Leipzig, Germany
        • Research Site
  • Greece
      • N. Faliro, Greece
        • Research Site
      • Patras, Greece
        • Research Site
      • Thessaloniki, Greece
        • Research Site
  • Hong Kong
      • Hong Kong, Hong Kong
        • Research Site
  • India
      • Ahmedabad, India
        • Research Site
      • Vellore, India
        • Research Site
  • Israel
      • Beer-Sheeva, Israel
        • Research Site
      • Haifa, Israel
        • Research Site
      • Jerusalem, Israel
        • Research Site
      • Kfar Saba, Israel
        • Research Site
      • Petach-Tikva, Israel
        • Research Site
      • Safed, Israel
        • Research Site
      • Tel-Hashomer, Israel
        • Research Site
      • Zerifin, Israel
        • Research Site
  • Italy
      • Genova, Italy
        • Research Site
      • Milano, Italy
        • Research Site
      • Orbassano, Italy
        • Research Site
      • Roma, Italy
        • Research Site
      • S.Andrea Delle Fratte, Italy
        • Research Site
  • Mexico
      • Aguascalientes, Mexico
        • Research Site
      • Mexico, Mexico
        • Research Site
      • Puebla, Mexico
        • Research Site
  • Philippines
      • Cebu City, Philippines
        • Research Site
      • Manila, Philippines
        • Research Site
      • Pasay City, Philippines
        • Research Site
      • Quezon City, Philippines
        • Research Site
  • Portugal
      • Lisboa, Portugal
        • Research Site
      • Santa Maria da Feira, Portugal
        • Research Site
      • Setúbal, Portugal
        • Research Site
  • South Africa
      • Cape Town, South Africa
        • Research Site
      • Durban, South Africa
        • Research Site
      • Johannesburg, South Africa
        • Research Site
      • Port Elizabeth, South Africa
        • Research Site
      • Pretoria, South Africa
        • Research Site
  • Spain
      • A Coruña, Spain
        • Research Site
      • Lugo, Spain
        • Research Site
      • Majadahonda, Spain
        • Research Site
      • Mataró(Barcelona), Spain
        • Research Site
      • Málaga, Spain
        • Research Site
      • Orense, Spain
        • Research Site
      • Santiago De Compostela(A Coru, Spain
        • Research Site
      • Vigo(Pontevedra), Spain
        • Research Site
  • Sweden
      • Lund, Sweden
        • Research Site
      • Sundsvall, Sweden
        • Research Site
      • Umeå, Sweden
        • Research Site
      • Uppsala, Sweden
        • Research Site
      • Västerås, Sweden
        • Research Site
  • Taiwan
      • Taipei, Taiwan
        • Research Site
  • United Kingdom
      • Birmingham, United Kingdom
        • Research Site
      • Edinburgh, United Kingdom
        • Research Site
      • Leeds, United Kingdom
        • Research Site
      • Manchester, United Kingdom
        • Research Site
      • Wolverhampton, United Kingdom
        • Research Site
  • United States
    • Arizona
      • Casa Grande, Arizona, United States
        • Research Site
      • Chandler, Arizona, United States
        • Research Site
    • Connecticut
      • Farmington, Connecticut, United States
        • Research Site
      • Stamford, Connecticut, United States
        • Research Site
    • District of Columbia
      • Washington, District of Columbia, United States
        • Research Site
    • Florida
      • Orlando, Florida, United States
        • Research Site
    • Georgia
      • Gainesville, Georgia, United States
        • Research Site
    • Illinois
      • Skokie, Illinois, United States
        • Research Site
    • Iowa
      • Sioux City, Iowa, United States
        • Research Site
    • Kentucky
      • Mount Sterling, Kentucky, United States
        • Research Site
    • Maine
      • Portland, Maine, United States
        • Research Site
    • Maryland
      • Baltimore, Maryland, United States
        • Research Site
      • Rockville, Maryland, United States
        • Research Site
    • Massachusetts
      • Boston, Massachusetts, United States
        • Research Site
    • Missouri
      • Saint Louis, Missouri, United States
        • Research Site
    • New York
      • Mineola, New York, United States
        • Research Site
      • Rochester, New York, United States
        • Research Site
    • North Carolina
      • Winston-Salem, North Carolina, United States
        • Research Site
    • Ohio
      • Cincinnati, Ohio, United States
        • Research Site
      • Middletown, Ohio, United States
        • Research Site
    • South Carolina
      • Hilton Head Island, South Carolina, United States
        • Research Site
    • Texas
      • Austin, Texas, United States
        • Research Site
    • Utah
      • Salt Lake City, Utah, United States
        • Research Site
  • Venezuela
      • Caracas, Venezuela
        • Research Site
      • Valencia, Venezuela
        • Research Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Provision of informed consent
  • Female or male aged 18 years or above
  • Histologic or cytologic confirmation of locally advanced or metastatic NSCLC (stage IIIB or IV) on entry into study
  • Failure of 1st line anti-cancer therapy (either radiological documentation of disease progression or due to toxicity) or subsequent relapse of disease following 1st line therapy
  • WHO Performance status 0 - 2
  • One or more measurable lesions at least 10 mm in the longest diameter (LD) by spiral CT scan or 20 mm with conventional techniques according to RECIST criteria. Previously irradiated lesions will not be considered measurable.
  • Life expectancy of 12 weeks or longer
  • Negative pregnancy test for women of childbearing potential only

Exclusion Criteria:

  • Mixed small cell and non-small cell lung cancer histology
  • Patients have received 2nd-line or subsequent anti-cancer therapy
  • Prior treatment with pemetrexed
  • Prior treatment with VEGFR TKIs (previous treatment with bevacizumab [Avastin] is permitted)
  • Known or suspected brain metastases or spinal cord compression, unless treated at least 4 weeks before entry, and stable without steroid treatment for 10 days
  • The last radiation therapy within 4 weeks before the start of study therapy, not including local palliative radiation
  • The last dose of prior chemotherapy or other anti-cancer therapy is discontinued less than 3 weeks before the start of study therapy (6 weeks for nitrosoureas, mitomycin, and suramin)
  • Major surgery within 4 weeks before entry, or incompletely healed surgical incision
  • Neutrophils <1.5 x 109/L or platelets <100 x 109/L
  • Serum bilirubin >1.5 x the upper limit of reference range (ULRR)
  • Creatinine clearance <50 ml/min calculated by either Cockcroft -Gault, 24 hours urine collection, EDTA scan or other validated methods
  • Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2.5 x ULRR in the absence of liver metastases, or > 5 x ULRR in the presence of liver metastases
  • Alkaline phosphatase (ALP) >2.5 x ULRR in the absence of liver metastases, or >5 x ULRR in the presence of liver metastases
  • Current active gastrointestinal disease that may affect the ability of the patient to absorb ZD6474 or tolerate diarrhoea
  • Evidence of severe or uncontrolled systemic disease or any concurrent condition which in the investigator's opinion makes it undesirable for the patient to participate in the study or which would jeopardize compliance with the protocol
  • Any unresolved toxicity greater than CTCAE Grade 2 from previous anti-cancer therapy
  • Significant cardiovascular event (e.g., myocardial infarction, superior vena cava [SVC] syndrome), New York Heart Association [NYHA] classification of heart disease ≥2 within 3 months before entry, or presence of cardiac disease that in the opinion of the Investigator increases the risk of ventricular arrhythmia
  • History of arrhythmia (multifocal premature ventricular contractions [PVCs], bigeminy, trigeminy, ventricular tachycardia, or uncontrolled atrial fibrillation) which is symptomatic or requires treatment (CTCAE grade 3) or asymptomatic sustained ventricular tachycardia. Atrial fibrillation, controlled on medication is not excluded
  • Congenital long QT syndrome or 1st degree relative with unexplained sudden death under 40 years of age
  • QT prolongation with other medications that required discontinuation of that medication
  • Presence of left bundle branch block (LBBB)
  • QTc with Bazett's correction unmeasurable or ≥ 480 msec on screening ECG (Note: If a patient has QTc interval ≥480 msec on screening ECG, the screen ECG may be repeated twice [at least 24 hours apart]. The average QTc from the three screening ECGs must be <480 msec in order for the patient to be eligible for the study) Patients who are receiving a drug that has a risk of QTc prolongation are eligible if QTc is <460 msec.
  • Potassium <4.0 mmol/L despite supplementation; serum calcium (or ionized or adjusted for albumin), or magnesium out of normal range despite supplementation
  • Women who are pregnant or breast-feeding
  • Any concomitant medications that may cause QTc prolongation or induce Torsades de Pointes or induce CYP3A4 function. Drugs that have a risk of QTc prolongation, that in the investigator's opinion cannot be discontinued, are allowed, but only of the QTc is <460 msec
  • Hypertension not controlled by medical therapy (systolic blood pressure greater than 160 millimetre of mercury [mmHg] or diastolic blood pressure greater than 100 mmHg)
  • Previous or current malignancies of other histologies within the last 5 years, with the exception of in situ carcinoma of the cervix and adequately treated basal cell or squamous cell carcinoma of the skin
  • Treatment with a non-approved or investigational drug within 30 days before Day 1 of study treatment
  • Concomitant use of yellow fever vaccine or any live attenuated vaccines

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Placebo Comparator: 1
Placebo Vandetanib + Pemetrexed
Drug: Pemetrexed
intravenous infusion
Other Names:
  • Alimta®
  • Pemetrexed disodium
Experimental: 2
Vandetanib + Pemetrexed
Drug: Pemetrexed
intravenous infusion
Other Names:
  • Alimta®
  • Pemetrexed disodium
Drug: Vandetanib
oral once daily tablet
Other Names:
  • ZD6474
  • ZACTIMA™
  • SAR390530

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Progression-Free Survival (PFS) in the Overall Population
Time Frame: RECIST tumour assessments carried out every 6 weeks (+/- 3 days) from randomization until objective progression
Median time (in weeks) from randomization until objective disease progression or death (by any cause in the absence of objective progression) provided death is within 3 months from the last evaluable Response Evaluation Criteria in Solid Tumors (RECIST) assessment.
RECIST tumour assessments carried out every 6 weeks (+/- 3 days) from randomization until objective progression
Progression-Free Survival in the Female Population
Time Frame: RECIST tumour assessments carried out every 6 weeks (+/- 3 days) from randomization until objective progression
Median time (in weeks) from randomization until objective disease progression or death (by any cause in the absence of objective progression) provided death is within 3 months from the last evaluable RECIST assessment.
RECIST tumour assessments carried out every 6 weeks (+/- 3 days) from randomization until objective progression

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Overall Survival (OS)
Time Frame: Time to death in months
The OS is defined as the time from date of randomization until death. Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive (i.e, their status must be known at the censored date and should not be lost to follow up or unknown).
Time to death in months
Objective Response Rate (ORR)
Time Frame: Each participant was assessed for objective response from the sequence of RECIST scan data up to data cut off. RECIST tumour assessments carried out every 6 weeks (+/- 3 days) from randomization until objective progression
The ORR is the number of participants that are responders i.e, those participants with a confirmed best objective response of complete response (CR) or partial response (PR) as defined by RECIST criteria. The categories for best objective response are CR, PR, stable disease (SD)>= 6 weeks, progressive disease (PD) or NE.
Each participant was assessed for objective response from the sequence of RECIST scan data up to data cut off. RECIST tumour assessments carried out every 6 weeks (+/- 3 days) from randomization until objective progression
Disease Control Rate (DCR)
Time Frame: RECIST tumour assessments carried out every 6 weeks (+/- 3 days) from randomization until objective progression
The DCR is defined as the number of patients who achieved disease control at 6 weeks following randomization. Disease control at 6 weeks is defined as a best objective response of complete response (CR), partial response (PR) or stable disease (SD) >= 6 weeks.
RECIST tumour assessments carried out every 6 weeks (+/- 3 days) from randomization until objective progression
Duration of Response (DoR)
Time Frame: RECIST tumour assessments carried out every 6 weeks (+/- 3 days) from randomization until objective progression
Response is defined as a confirmed best objective response of CR or PR. Duration of response is defined as time from the date of first documented response until date of documented progression or death in the absence of disease progression (provided death is within 3 months of last RECIST assessment).
RECIST tumour assessments carried out every 6 weeks (+/- 3 days) from randomization until objective progression
Time to Deterioration of Disease-Related Symptoms (TDS) by Lung Cancer Symptom Scale (LCSS) Total Score
Time Frame: LCSS questionnaires are to be administered every 3 weeks after randomization
TDS is the interval from the date of randomization to the first assessment of worsened without an improvement in the next 21 days. A deterioration in symptoms is defined as a single visit assessment of 'worsened' with no visit assessment of 'improved' within the next 21 days. The LCSS scale measures changes in symptoms associated with lung cancer.
LCSS questionnaires are to be administered every 3 weeks after randomization
Time to Deterioration of Disease-Related Symptoms by Average Symptom Burden Index (ASBI) Score
Time Frame: ASBI is a score taken from the LCSS questionnaires which are to be administered every 3 weeks after randomization
Time to deterioration is defined as the interval from the date of randomization to the first assessment of worsened without an improvement in the next 21 days. A deterioration in symptoms is defined as a single visit assessment of 'worsened' with no visit assessment of 'improved' within the next 21 days. The ASBI is derived from 6 of LCSS's 9 items.
ASBI is a score taken from the LCSS questionnaires which are to be administered every 3 weeks after randomization
Longitudinal Analysis of Lung Cancer Symptom Scale Total Score
Time Frame: LCSS questionnaires are to be administered every 3 weeks after randomization
The longitudinal data analysis will include all non-missing visit scores and the model will include only the first 12 weeks of data. LCSS total score is an average of all 9 visual analogue participant scales from "none" [0 millimeter (mm)] to "as much as it could be" (100 mm).
LCSS questionnaires are to be administered every 3 weeks after randomization
Longitudinal Analysis of Average Symptom Burden Index Score
Time Frame: ASBI is a score taken from the LCSS questionnaires administered every 3 weeks after randomization
The longitudinal data analysis will include all non-missing visit scores and the model will include only the first 12 weeks of data. ASBI is an average of the 6 symptom visual analogue patient scales from "none" (0 mm) to "as much as it could be" (100 mm).
ASBI is a score taken from the LCSS questionnaires administered every 3 weeks after randomization

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Genzyme, a Sanofi Company

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Study Director: Clinical Sciences & Operations, Sanofi

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
January 1, 2007

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
September 1, 2008

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
February 14, 2023

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
January 4, 2007

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
January 4, 2007

First Posted (Estimated)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
January 5, 2007

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
March 25, 2025

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
December 23, 2024

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
December 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • D4200C00036
  • EUDRACT No. 2006-003695-35
  • LPS15296 (Other Identifier: Sanofi)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings